| Identification | Back Directory | [Name]
4H-1-Benzopyran-4-one, 6-methyl-2-(4-morpholinyl)-8-[1-(phenylamino)ethyl]- | [CAS]
901398-68-3 | [Synonyms]
PIK-108
4H-1-Benzopyran-4-one, 6-methyl-2-(4-morpholinyl)-8-[1-(phenylamino)ethyl]- | [Molecular Formula]
C22H24N2O3 | [MOL File]
901398-68-3.mol | [Molecular Weight]
364.44 |
| Chemical Properties | Back Directory | [Boiling point ]
545.6±50.0 °C(Predicted) | [density ]
1.252±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 50 mg/mL (137.20 mM; Need ultrasonic) | [form ]
Solid | [pka]
4.19±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
PIK-108 is a non-ATP competitive, allosteric p110β/p110δ selective inhibitor[1]. | [Biological Activity]
PIK-108 is a non-ATP competitive, allosteric p110β/p110δ selective inhibitor[1].
PIK-108 (0.1-10 μM; 1 hour) blocks phosphorylation of PKB/Akt[1]. | [References]
[1]. Zachary A Knight, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47. [2]. Jack S Chen, et al. Characterization of structurally distinct, isoform-selective phosphoinositide 3’-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol Cancer Ther. 2008 Apr;7(4):841-50. |
|
|